2016

Genitourinary-Cancer-Meeting

My videos
Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunotherapy
00:01:28

Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunotherapy
119 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Using Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements
00:01:25

Using Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements
129 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients
00:04:30

Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients
184 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Subgroup analyses of METEOR
00:01:33

Subgroup analyses of METEOR
373 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
CheckMate 025 phase III trial
00:01:22

CheckMate 025 phase III trial
425 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Immunotherapy in non muscle invasive bladder cancer #GU16
00:00:37

Immunotherapy in non muscle invasive bladder cancer #GU16
562 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
How soon should we expect approval of immunotherapy in urothelial cancer #GU16
00:00:38

How soon should we expect approval of immunotherapy in urothelial cancer #GU16
390 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Future role of immunotherapy and checkpoint inhibitors in urothelial cancer #GU16
00:00:44

Future role of immunotherapy and checkpoint inhibitors in urothelial cancer #GU16
603 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Atezolizumab shows very significant activity in advanced urothelial cancer #GU16
00:00:54

Atezolizumab shows very significant activity in advanced urothelial cancer #GU16
468 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC #GU16
00:01:21

Discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC #GU16
322 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Genomics in urothelial carcinomas may play much bigger role in the future #GU16
00:02:17

Genomics in urothelial carcinomas may play much bigger role in the future #GU16
396 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Inhibiting autophagy in bladder cancer #GU16
00:02:14

Inhibiting autophagy in bladder cancer #GU16
238 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Clinical and pathological factors that can influence outcomes in upper tract urothelial cancer #GU16
00:01:29

Clinical and pathological factors that can influence outcomes in upper tract urothelial cancer #GU16
223 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Does treatment for prior cancer develop secondary bladder cancer #gu16
00:01:54

Does treatment for prior cancer develop secondary bladder cancer #gu16
385 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Annual Meeting GU 2016 Role of neoadjuvant chemotherapy and the impact of the latest randomized trials in bladder cancer
00:01:42

Annual Meeting GU 2016 Role of neoadjuvant chemotherapy and the impact of the latest randomized trials in bladder cancer
804 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Annual Meeting GU 2016 Immune checkpoint inhibitors in combination with chemotherapy or targeted agents for urothelial cancers
00:00:42

Annual Meeting GU 2016 Immune checkpoint inhibitors in combination with chemotherapy or targeted agents for urothelial cancers
394 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Annual Meeting GU 2016 Clinical trials in bladder cancer with Atezolizumab and Pembrolizumab
00:02:55

Annual Meeting GU 2016 Clinical trials in bladder cancer with Atezolizumab and Pembrolizumab
454 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Annual Meeting GU 2016 Adjuvant radiation v. chemo-RT v. chemotherapy alone after radical cystectomy for locally advanced bladder cancer
00:01:25

Annual Meeting GU 2016 Adjuvant radiation v. chemo-RT v. chemotherapy alone after radical cystectomy for locally advanced bladder cancer
467 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Annual Meeting GU 2016 Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer
00:02:07

Annual Meeting GU 2016 Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer
371 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Recommendations for the utilization of molecular factors in treatment planning for localized prostate cancer Annual Meeting GU 2016
00:01:23

Recommendations for the utilization of molecular factors in treatment planning for localized prostate cancer Annual Meeting GU 2016
910 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Ongoing clinical trials that will establish a clinical role for molecular risk factors in prostate cancer
00:00:51

Ongoing clinical trials that will establish a clinical role for molecular risk factors in prostate cancer
251 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Molecular markers that have been identified in prognosis and risk of relapse in localized prostate cancer.
00:00:43

Molecular markers that have been identified in prognosis and risk of relapse in localized prostate cancer.
320 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Molecular markers have greater impact on risk of recurrence than cancer stage and PSA levels
00:00:36

Molecular markers have greater impact on risk of recurrence than cancer stage and PSA levels
241 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Annual Meeting GU 2016 Genetic Testing in Prostate Cancer
00:01:12

Annual Meeting GU 2016 Genetic Testing in Prostate Cancer
465 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login